AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6373442
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 25 mg b.i.d.
Trial: 6373442
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 50 mg b.i.d.
Trial: 31343273
Drug: Psychiatric medications
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric medications (n=21)
Trial: 31343273
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n=35)
Trial: 28320323
Drug: Rocuronium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium administered with closed-loop feedback infusion system in group laparoscopy
Trial: 28320323
Drug: Rocuronium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium administered with closed-loop feedback infusion system in group control
Trial: 24634065
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) delivered in groups
Trial: 19765815
Drug: Mefloquine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (125 mg)
Trial: 19765815
Drug: Sulfadoxine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine (250 mg) plus pyrimethamine (12.5 mg)
Trial: 19765815
Drug: Chlorproguanil (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorproguanil (15 mg) plus dapsone (18.75 mg)
Trial: 11208630
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled albuterol (100 microg per puff, in 2 puffs four times daily)
Trial: 9565263
Drug: IMZ implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMZ implants connected by a Dolderbar
Trial: 8667280
Drug: Transmandibular implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmandibular implant (TMI)
Trial: 3421513
Drug: Intravenous atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atenolol (0.05 and 0.10 mg/kg)
Trial: 3421513
Drug: Oral atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atenolol (50 and 100 mg)
Trial: 25588408
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment with donepezil only)
Trial: 17318860
Drug: New adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New adjuvanted hepatitis B vaccine
Trial: 17318860
Drug: Conventional vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional vaccine (booster)
Trial: 9680894
Drug: alpha-tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol (50 mg per day)
Trial: 9680894
Drug: beta-carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-carotene (20 mg per day)
Trial: 7976797
Drug: Dimethindene maleate
RxNorm normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethindene maleate (DMM) 4 mg
Trial: 7976797
Drug: Dimethindene maleate
RxNorm normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethindene maleate (DMM) 8 mg
Trial: 28150423
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetyl hexapeptide‐3 with tripeptide‐10 citrulline (Group G1)
Trial: 21921843
Drug: Lipiodol (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol (doxorubicin 30 mg/m plus cisplatin 100 mg/m with lipiodol emulsification)
Trial: 21921843
Drug: Solution (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution (doxorubicin 30 mg/m plus cisplatin 100 mg/m without lipiodol emulsification)
Trial: 14695863
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 300,000 units of vitamin D(2)
Trial: 14695863
Drug: Injected vitamin
RxNorm normalized name: vitamin A Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected vitamin D(2) plus 1 g/day oral calcium
Trial: 14695863
Drug: 800 units/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 units/day oral vitamin D(3) plus 1 g/day calcium
Trial: 11573063
Drug: Glucose 50%
RxNorm normalized name: glucose 50% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 50% solution
Trial: 11573063
Drug: Sucrose 33%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose 33% solution
Trial: 11573063
Drug: Sucrose 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose 50% solution
Trial: 9724481
Drug: Intravenous prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostaglandin E1 (PGE1) administered by continuous infusion at a dose of 10 to 40 microg/h as tolerated
Trial: 7663659
Drug: rhDNase twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNase twice daily
Trial: 3057041
Drug: Azelastine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 2.0 mg twice daily
Trial: 3057041
Drug: Azelastine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 0.5 mg and 1.0 mg
Trial: 3057041
Drug: Chlorpheniramine 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 4.0 mg four times daily
Trial: 3057041
Drug: Azelastine (high-dose)
RxNorm normalized name: azelastine Metered Dose Nasal Spray
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine (high-dose)
Trial: 31899602
Drug: Ubrogepant 150
RxNorm normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ubrogepant 150 mg daily for 28 days
Trial: 31899602
Drug: Ubrogepant (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubrogepant (100-400 mg single and multiple ascending doses)
Trial: 26440829
Drug: Home-based pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based pulmonary rehabilitation (education about the disease, diet therapy, stress reduction methods, effective cough, breathing exercises, muscle stretching exercises) practiced at home three times per week for 7 weeks.
Trial: 26440829
Drug: Routine visits
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine visits and weekly telephone follow-up (Control group).
Trial: 23436437
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa oil (2.5 mL, two times a day for 8 weeks)
Trial: 23436437
Drug: Placebo (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.5 mL, two times a day for 8 weeks)
Trial: 16683383
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation radiation therapy (CFRT)
Trial: 16683383
Drug: CFRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFRT plus concomitant chemotherapy (CT)
Trial: 8279248
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with Diclofenac
Trial: 24424073
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 5000 IU daily for 28 days
Trial: 24290111
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 150,000 IU cholecalciferol
Trial: 22024477
Drug: Preoperative inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative inhalation of milrinone (Mil group)
Trial: 16353851
Drug: Mapping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mapping therapy for sentence production
Trial: 8270443
Drug: External-beam radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: External-beam radiation therapy plus 5-fluorouracil (5-FU)
Trial: 8270443
Drug: External-beam radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: External-beam radiation therapy plus hycanthone (HYC)
Trial: 2913977
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin with dihydroergotamine (A)
Trial: 2913977
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin with dihydroergotamine (B)
Trial: 4601222
Drug: 26° ‐adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26° ‐adapted RSV vaccine (28 children)
Trial: 31174514
Drug: Screen-Refer-Treat (SRT)
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screen-Refer-Treat (SRT) model including universal Stage 1 ASD screening, immediate referral to community-based EI program, and provision of evidence-based ASD-specialized treatment.
Trial: 15143716
Drug: Xuesaitong capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuesaitong capsule (PNS)
Trial: 14999615
Drug: GBS type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS type V CPS‐tetanus toxoid (TT) vaccine
Trial: 14999615
Drug: GBS type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS type V CPS‐cross‐reactive material (CRM(197)) conjugate vaccine
Trial: 10355575
Drug: Ibandronate 50
RxNorm normalized name: ibandronic acid 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 50 mg
Trial: 10355575
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg
Trial: 10355575
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg
Trial: 10355575
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg
Trial: 10355575
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg
Trial: 8955653
Drug: 5‐FU 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 10 mg/m2 orally
Trial: 8955653
Drug: 5‐FU 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 10 to 25 mg/m2/d orally for 5 days with 776C85 3.7 mg/m2/d orally
Trial: 8955653
Drug: 776C85 3.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 776C85 3.7 mg/m2/d orally
Trial: 8955653
Drug: 5‐FU oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU oral route
Trial: 7043497
Drug: Neurotropic drug
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropic drug (tamitinol dihydrochloride coated tablets of 300 mg t.i.d.)
Trial: 30916527
Drug: Wrist joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist joint splinting combined with physical therapy
Trial: 26991616
Drug: Single-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose group (15 mg/kg TXA before surgery and saline 3 hours later)
Trial: 26991616
Drug: 2-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose group (10 mg/kg TXA before and 10 mg/kg TXA 3 hours after surgery)
Trial: 23177418
Drug: Single-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose group
Trial: 26991616
Drug: 2-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose group
Trial: 24289892
Drug: Fluoxetine (40mg/day)
RxNorm normalized name: fluoxetine 40 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40mg/day)
Trial: 21604039
Drug: Arthroscopic implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic implant removal
Trial: 21604039
Drug: Open implant
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open implant removal
Trial: 31074178
Drug: Anamorelin 5
RxNorm normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anamorelin 5 mg
Trial: 31074178
Drug: Anamorelin 25
RxNorm normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anamorelin 25 mg
Trial: 31074178
Drug: Anamorelin 25
RxNorm normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anamorelin 25 mg and 50 mg
Trial: 26742380
Drug: Commercial anti-fogging
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial anti-fogging solution (Ultrastop®)
Trial: 26742380
Drug: Baby shampoo
RxNorm normalized name: BABY SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby shampoo solution (Johnson's® no more tear®)
Trial: 23002172
Drug: Oral Appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Appliances (OAs)
Trial: 21219381
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (EPA and DHA), 1.84 g per day for 32 weeks
Trial: 19633072
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with MetS with insulin resistance (IR)
Trial: 14985485
Drug: Infliximab maintenance
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab maintenance therapy (5 mg/kg every 8 weeks)
Trial: 11527647
Drug: Echocardiography with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echocardiography with harmonic imaging and contrast injection
Trial: 11527647
Drug: Echocardiography without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Echocardiography without contrast injection
Trial: 11527647
Drug: Echocardiography with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echocardiography with contrast injection
Trial: 9481960
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetaminophen with 10 mg hydrocodone
Trial: 9481960
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ketoprofen
Trial: 3105913
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 1.75 mg/kg given over 12 hr (0.75 mg/kg over 1 hr, 0.5 mg/kg over 4 hr, and 0.5 mg/kg over 7 hr)
Trial: 2858711
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA)
Trial: 31077582
Drug: BT-11 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT-11 (up to 100 mg/kg, p.o.)
Trial: 31077582
Drug: BT-11 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT-11 (up to 100 mg/kg daily for seven days, orally)
Trial: 31077582
Drug: BT-11 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT-11 (multiple ascending doses)
Trial: 31077582
Drug: BT-11 (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT-11 (0.01 µM ex vivo treatment)
Trial: 30915987
Drug: PNK (paracetamol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNK (paracetamol, nefopam, ketoprofen)
Trial: 28214613
Drug: Standardized skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized skin care regimens (body wash and twice daily applications of leave-on products for eight weeks)
Trial: 23470803
Drug: High-dose DRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DRI (300 mg per day)
Trial: 23470803
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (standard dose DRI 150 mg + hydrochlorothiazide 12.5 mg)
Trial: 23470803
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose DRI (150 mg)
Trial: 17060046
Drug: Pentoxifylline (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (continuous infusion of 1.5 mg/kg per hour during operation)
Trial: 13129633
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (including radiation treatment alone)
Trial: 10638985
Drug: Cimetidine (H2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (H2 antagonist), preoperative administration, dosage and duration not specified
Trial: 10638985
Drug: Cimetidine (H2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (H2 antagonist), preoperative administration
Trial: 9344321
Drug: High-dose rTNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rTNF alpha + interferon-gamma + melphalan
Trial: 2863393
Drug: Intracorporeal injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracorporeal injection of 5 mg phentolamine
Trial: 28793884
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (control group)
Trial: 20803065
Drug: FEC90 ×4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC90 ×4 cycles followed by eight doses of weekly paclitaxel (T)
Trial: 17009401
Drug: S-pantoprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-pantoprazole (20 mg once a day)
Trial: 17009401
Drug: racemic pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: racemic pantoprazole (40 mg once a day)
Trial: 15213583
Drug: Methylphenidate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate plus multimodal psychosocial treatment (including social skills training)
Trial: 7917930
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g of glutamine per day for 8 days
Trial: 3140688
Drug: Flumazenil (Anexate)
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil (Anexate) administered postoperatively in incremental doses up to 1 mg
Trial: 3140688
Drug: Flumazenil (Anexate)
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil (Anexate) administered postoperatively
Trial: 18838750
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine sulphate 10 mg
Trial: 18838750
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac suppository 100 mg
Trial: 16652054
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) and adherence support (AT)
Trial: 12958329
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with perindopril (4 mg/d) and diuretic indapamide (as needed)
Trial: 10980588
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (NA) 500 mg daily for 7 days
Trial: 10980588
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (NA) 1 g daily for a further 7 days
Trial: 1611830
Drug: Insulin Tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Tolerance Test (ITT) with 0.1 U kg‐1 body weight, human Actrapid insulin given as an IV bolus; KITT measured over the period 3-15 min.
Trial: 1611830
Drug: Euglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemic clamp with insulin infusion of 50 mU kg‐1 h‐1 for 120 min; M/I values derived from the clamp.
Trial: 29301520
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg once daily for 6 weeks
Trial: 20729538
Drug: DHEA (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (75 mg once a day before and during IVF treatment)
Trial: 15714184
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (10 mg of 0.5% hyperbaric bupivacaine)
Trial: 10665626
Drug: Divalproex oral
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex oral loading (30 mg/kg/day on days 1 and 2, followed by 20 mg/kg/day on days 3‐10)
Trial: 10665626
Drug: Divalproex nonloading
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex nonloading (starting dose of 250 mg t.i.d. on days 1 and 2, followed by standard dose titration for days 3 to 10)